Gameto
its Fertilo platform uses engineered ovarian support cells derived from hiPSCs to mature eggs outside the body in roughly one day of co-culture, shortening IVF/egg-freezing cycles from about 14 days to 3; it holds FDA IND clearance and has entered a US Phase 3 trial,…
- Country
- United States
ivg
reproductive-medicine
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| In-vitro gametogenesis (IVG) & reproductive synbio | regenerative-personalized | High | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.